Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications

Gulati, Neetu M.; Stewart, Phoebe L.; Steinmetz, Nicole F.

doi:10.1021/acs.molpharmaceut.8b00292

Cited by 94 publications

(84 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most obvious hurdle is whether pre-existing or de novo acquired adaptive immunity against the viral carrier would lead to adverse effects or reduce efficacy upon repeat administration [230]. This may be a challenge for traditional drug delivery approaches targeting diseased cells and tissueshowever, surface passivation or immune editing methods have shown promise [231][232][233]. When it comes to immunotherapy applications, the immunogenicity of the carrier is less likely to be a barrier.…”

Section: Challenges Moving Forward and Future Directionsmentioning

confidence: 99%

Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications

Chung

Cai

Steinmetz

2020

Advanced Drug Delivery Reviews

Self Cite

298

241

View full text Add to dashboard Cite

Viral nanoparticles (VNPs) encompass a diverse array of naturally occurring nanomaterials derived from plant viruses, bacteriophages, and mammalian viruses. The application and development of VNPs and their genomefree versions, the virus-like particles (VLPs), for nanomedicine is a rapidly growing. VLPs can encapsulate a wide range of active ingredients as well as be genetically or chemically conjugated to targeting ligands to achieve tissue specificity. VLPs are manufactured through scalable fermentation or molecular farming, and the materials are biocompatible and biodegradable. These properties have led to a wide range of applications, including cancer therapies, immunotherapies, vaccines, antimicrobial therapies, cardiovascular therapies, gene therapies, as well as imaging and theranostics. The use of VLPs as drug delivery agents is evolving, and sufficient research must continuously be undertaken to translate these therapies to the clinic. This review highlights some of the novel research efforts currently underway in the VNP drug delivery field in achieving this greater goal.

show abstract

Section: Challenges Moving Forward and Future Directionsmentioning

confidence: 99%

Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications

Chung

Cai

Steinmetz

2020

Advanced Drug Delivery Reviews

Self Cite

298

241

View full text Add to dashboard Cite

show abstract

“…These biomimetic design strategies use different cell types such as red blood cells, platelets, leucocytes, cancer cells and stem cells. Nevertheless, a possible major issue is reorienting the targeted bio-inspired nanoparticles to a specific bodily location; for instance, delivering platelet membrane-coated nanoparticles away from sites of vascular injury may be a larger hurdle [23]. Unlike optimizing nanoparticle design, direct blockade of the MPS has gained increasing attention.…”

Section: Introductionmentioning

confidence: 99%

A combined “eat me/don't eat me” strategy based on extracellular vesicles for anticancer nanomedicine

Belhadj

Deng

et al. 2020

J of Extracellular Vesicle

148

109

View full text Add to dashboard Cite

A long-term and huge challenge in nanomedicine is the substantial uptake and rapid clearance mediated by the mononuclear phagocyte system (MPS), which enormously hinders the development of nanodrugs. Inspired by the natural merits of extracellular vesicles, we therefore developed a combined "eat me/don't eat me" strategy in an effort to achieve MPS escape and efficient drug delivery. Methodologically, cationized mannan-modified extracellular vesicles derived from DC2.4 cells were administered to saturate the MPS (eat me strategy). Then, nanocarriers fused to CD47-enriched exosomes originated from human serum were administered to evade phagocytosis by MPS (don't eat me strategy). The nanocarriers were also loaded with antitumor drugs and functionalized with a novel homing peptide to promote the tumour tissue accumulation and cancer cell uptake (eat me strategy). The concept was proven in vitro as evidenced by the reduced endocytosis of macrophages and enhanced uptake by tumour cells, whereas prolonged circulation time and increased tumour accumulation were demonstrated in vivo. Specially, the strategy induced a 123.53% increase in tumour distribution compared to conventional nanocarrier. The study both shed light on the challenge overcoming of phagocytic evasion and provided a strategy for significantly improving therapeutic outcomes, potentially permitting active drug delivery via targeted nanomedicines.

show abstract

“…Among the aforementioned synthetic polymers, PG, PVP, and PHPMA have been considered as the most promising alternatives to PEG [20]. However, the repeated administration of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76]. good solubility in both hydrophilic and hydrophobic solvents [72], and they have been reported to be both highly resistant to oxidative degradation and not undergo bioaccumulation [28].…”

Section: Hydrophilic Polymersmentioning

confidence: 99%

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

et al. 2020

View full text Add to dashboard Cite

Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.

show abstract

Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications

Cited by 94 publications

References 98 publications

Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications

Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications

A combined “eat me/don't eat me” strategy based on extracellular vesicles for anticancer nanomedicine

The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation

Contact Info

Product

Resources

About